Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Chorea

ClinicalTrials.gov lists 310 trials for Chorea or a narrower condition beneath it. Pfizer has the most among industry and government lead sponsors, with 12.

MeSH D002819 Nervous System Diseases C10 C23 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 46 Phase 1/2 Phase 1/2 18 Phase 2 Phase 2 51 Phase 2/3 Phase 2/3 7 Phase 3 Phase 3 25 Phase 4 Phase 4 5 Not applicable Not applicable 64 Observational Observational 93 Phase 1 Phase 1 46 Phase 1/2 Phase 1/2 18 Phase 2 Phase 2 51 Phase 2/3 Phase 2/3 7 Phase 3 Phase 3 25 Phase 4 Phase 4 5 Not applicable Not applicable 64 Observational Observational 93

Trials per phase

1 more section with rows

42 of the 310 trials are tagged with Chorea itself; the rest are tagged with a narrower condition beneath it.

Get the Chorea report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Chorea trials start? (30)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 28

1990: 1 trials (Observational 1) 1993: 1 trials (Observational 1) 1999: 3 trials (Observational 1, Phase 3 1, Phase 2 1) 2000: 1 trials (Observational 1) 2001: 3 trials (Observational 1, Phase 1/2 2) 2002: 3 trials (Observational 1, Not applicable 1, Phase 2 1) 2003: 3 trials (Observational 3) 2004: 4 trials (Observational 1, Phase 4 1, Phase 2 1, Phase 1 1) 2005: 6 trials (Observational 1, Phase 3 1, Phase 2 4) 2006: 4 trials (Observational 2, Phase 2/3 1, Phase 1/2 1) 2007: 7 trials (Observational 4, Phase 2 2, Phase 1 1) 2008: 7 trials (Not applicable 1, Phase 4 1, Phase 3 2, Phase 2 1, Phase 1 2) 2009: 22 trials (Observational 2, Not applicable 2, Phase 3 3, Phase 2 2, Phase 1 13) 2010: 5 trials (Observational 1, Phase 3 1, Phase 2/3 1, Phase 2 2) 2011: 15 trials (Observational 4, Not applicable 2, Phase 2 5, Phase 1 4) 2012: 8 trials (Observational 3, Not applicable 3, Phase 2 2) 2013: 11 trials (Observational 3, Not applicable 2, Phase 4 1, Phase 3 2, Phase 2 2, Phase 1 1) 2014: 12 trials (Observational 1, Not applicable 4, Phase 2 5, Phase 1/2 1, Phase 1 1) 2015: 14 trials (Not applicable 8, Phase 2 4, Phase 1/2 1, Phase 1 1) 2016: 11 trials (Observational 5, Not applicable 4, Phase 2 1, Phase 1 1) 2017: 15 trials (Observational 5, Not applicable 4, Phase 2 1, Phase 1/2 3, Phase 1 2) 2018: 10 trials (Observational 1, Not applicable 2, Phase 4 1, Phase 2 3, Phase 1 3) 2019: 15 trials (Observational 5, Not applicable 1, Phase 3 4, Phase 2 1, Phase 1/2 2, Phase 1 2) 2020: 18 trials (Observational 7, Not applicable 4, Phase 3 2, Phase 2/3 1, Phase 2 2, Phase 1/2 1, Phase 1 1) 2021: 20 trials (Observational 8, Not applicable 6, Phase 2/3 1, Phase 2 1, Phase 1/2 2, Phase 1 2) 2022: 19 trials (Observational 7, Not applicable 2, Phase 3 3, Phase 2 4, Phase 1/2 1, Phase 1 2) 2023: 13 trials (Observational 4, Not applicable 3, Phase 2 3, Phase 1/2 1, Phase 1 2) 2024: 28 trials (Observational 11, Not applicable 8, Phase 4 1, Phase 3 3, Phase 2 2, Phase 1 3) 2025: 18 trials (Observational 8, Not applicable 5, Phase 2/3 1, Phase 2 1, Phase 1/2 2, Phase 1 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 11
2025 18
2024 28
2023 13
2022 19
2021 20
2020 18
2019 15
2018 10
2017 15

Showing 10 of 30 earlier years.

Start your 14-day trial Email me all 30 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 15 trials starting in 2026 and about 17 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 32 trials still running at the 2026-10-09 snapshot; registered median of 26 months across 187 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Chorea trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 46
Phase 1/2 18
Phase 2 51
Phase 2/3 7
Phase 3 25
Phase 4 5
Not applicable 64
Observational 93
Expanded access 1

How many Chorea trials are recruiting? (9)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 6
Recruiting 44
Enrolling by invitation 3
Active, not recruiting 19
Completed 170

Showing 5 of 9 statuses.

Start your 14-day trial Email me all 9 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Chorea trials? (9)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Pfizer 12
Hoffmann-La Roche 9
Institut National de la Santé Et de la Recherche Médicale, France 8
University Hospital, Angers 7
Prilenia 6

Showing 5 of 9 sponsors.

Start your 14-day trial Email me all 9 sponsors as a PDF

Which drugs are being tested for Chorea? (7)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Pridopidine 8
Creatine 6
Valbenazine 4
SAGE-718 4
SD-809 4

Showing 5 of 7 drugs.

Start your 14-day trial Email me all 7 drugs as a PDF

Interventions as named in the registry (8)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Dimebon 9
RO7234292 4
SEN0014196 4
LPM3770164 sustained release tablet 3
SKY-0515 3

Showing 5 of 8 interventions.

Start your 14-day trial Email me all 8 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Chorea trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Fall 33 14
Suicide attempt 27 11
Suicidal ideation 22 10
SUICIDE ATTEMPT 21 2
Pneumonia 19 13

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Chorea? (72)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Safety and Efficacy of Deutetrabenazine at High versus Lower Daily Dosages in the ARC-HD Study to Treat Chorea in Huntington Disease. CNS drugs 2025 Yes
A proof-of-concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington's disease. British journal of clinical pharmacology 2023 Yes
Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet. Neurology 2023 Yes
Pediatric de novo movement disorders and ataxia in the context of SARS-CoV-2. Journal of neurology 2023 Yes
Deep brain stimulation and stereotactic-assisted brain graft injection targeting fronto-striatal circuits for Huntington's disease: an update. Expert review of neurotherapeutics 2022 Yes

Showing 5 of 72 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (3)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Benign hereditary chorea Point prevalence <1 / 1 000 000 Worldwide Not stated Unspecified
Paroxysmal dyskinesia Point prevalence Unknown Worldwide Not stated Exact
Paroxysmal dyskinesia Point prevalence Unknown Worldwide Not stated Exact

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Paroxysmal dyskinesia 1431 Exact Orphanet Rare Disease Ontology (ORDO)
Paroxysmal dyskinesia 1431 Exact Orphadata Science knowledge files, Product 1

Sub-conditions in MeSH (2)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Browse all condition evidence pages